Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

We kindly request your action: To continue receiving your Amedeo newsletters, please confirm your subscription by October 1, 2023.

Please check your weekly Amedeo newsletter.

  Breast Cancer

  Free Subscription


3 AJR Am J Roentgenol
2 Ann Oncol
8 Ann Surg Oncol
2 Anticancer Res
4 BMC Cancer
1 Br J Cancer
4 Breast Cancer
4 Breast Cancer Res
15 Breast Cancer Res Treat
1 Breast J
1 Cancer
2 Clin Breast Cancer
2 Clin Cancer Res
1 Discov Oncol
1 Int J Cancer
1 J Clin Invest
1 J Natl Cancer Inst
1 Nat Rev Cancer
1 Nature
1 NPJ Breast Cancer
1 Oncogene
6 PLoS One
5 Radiol Imaging Cancer
1 Radiology
1 Radiother Oncol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

    Editorial Comment: Closing the Gap-Emerging Role of Estrogen Receptor-Targeted PET in Invasive Lobular Carcinoma.
    AJR Am J Roentgenol. 2023;221:239.

  2. MEMA E, Lane EG, Drotman MB, Eisen CS, et al
    Axillary Lymphadenopathy After a COVID-19 Vaccine Booster Dose: Time to Resolution on Ultrasound Follow-Up and Associated Factors.
    AJR Am J Roentgenol. 2023 Mar 8. doi: 10.2214/AJR.22.28970.
    PubMed         Abstract available

  3. SINHA P, Lamonica DM
    Beyond the AJR: (99m)Tc-MDP Bone Scintigraphy-Has It Met Its Match?
    AJR Am J Roentgenol. 2023 Jan 11. doi: 10.2214/AJR.23.28978.

    Ann Oncol

  4. WEI T, Wang D, Yuan P
    The role of trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Ann Oncol. 2023 Jul 25:S0923-7534(23)00768-8. doi: 10.1016/j.annonc.2023.

  5. TARANTINO P, Tolaney SM, Curigliano G
    Trastuzumab deruxtecan (T-DXd) in HER2-low metastatic breast cancer treatment.
    Ann Oncol. 2023 Jul 25:S0923-7534(23)00767-6. doi: 10.1016/j.annonc.2023.

    Ann Surg Oncol

  6. ADESOYE T, Everidge S, Chen J, Sun SX, et al
    Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy.
    Ann Surg Oncol. 2023 Jul 21. doi: 10.1245/s10434-023-13906.
    PubMed         Abstract available

  7. HORAN J, Reid C, Boland MR, Daly GR, et al
    Assessing Mode of Recurrence in Breast Cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review.
    Ann Surg Oncol. 2023 Jul 21. doi: 10.1245/s10434-023-13885.
    PubMed         Abstract available

  8. SILVERSTEIN MJ, Kim B, Lin K, Lloyd S, et al
    ASO Visual Abstract: Risk-Adapted Intraoperative Radiation Therapy (IORT) for Breast Cancer-Novel Analysis.
    Ann Surg Oncol. 2023 Jul 22. doi: 10.1245/s10434-023-13980.

  9. MOLDOVEANU D, Goetz MP, Boughey JC
    ASO Author Reflections: Low Estrogen Receptor (ER) Expression Breast Cancer Behaves More like ER Negative Disease and Influences Management.
    Ann Surg Oncol. 2023 Jul 24. doi: 10.1245/s10434-023-13985.

  10. HUANG K, Jakub J, Gabriel E, Moreno-Aspitia A, et al
    Overall Survival Following Neoadjuvant Chemotherapy Versus Adjuvant Chemotherapy in Clinically Node Negative T1 Triple Negative Breast Cancer.
    Ann Surg Oncol. 2023 Jul 25. doi: 10.1245/s10434-023-13977.
    PubMed         Abstract available

  11. JONCZYK MM, Chatterjee A
    ASO Author Reflections: Enhancing Preoperative Decision-Making by Using the BCSRc to Predict Breast Cancer Surgery Complications.
    Ann Surg Oncol. 2023 Jul 25. doi: 10.1245/s10434-023-14025.

  12. NGUYEN CL, Zhou M, Easwaralingam N, Seah JL, et al
    ASO Visual Abstract: Novel Dual Tracer Indocyanine Green and Radioisotope Versus Gold Standard Sentinel Lymph Node Biopsy in Breast Cancer-The GREENORBLUE Trial.
    Ann Surg Oncol. 2023 Jul 27. doi: 10.1245/s10434-023-13997.

  13. CHU CD, Smith CE, Gorski J, Smolkin M, et al
    Implementation of a Novel Patient Decision Aid for Women with Elevated Breast Cancer Risk Who Are Considering MRI Screening: A Pilot Study.
    Ann Surg Oncol. 2023 Jul 28. doi: 10.1245/s10434-023-13901.
    PubMed         Abstract available

    Anticancer Res

  14. LEE YC, Tang CT, Kan JY, Chiang CP, et al
    Correlation of Beta2-Glycoprotein I With Tumor Prognosis in Breast Cancer Patients.
    Anticancer Res. 2023;43:3455-3462.
    PubMed         Abstract available

  15. JINGU K, Umezawa R, Yamamoto T, Takahashi N, et al
    Recent Postoperative Radiotherapy for Left-sided Breast Cancer Does Not Increase Mortality of Heart Disease in Asians or Pacific Islanders: SEER Database Analysis.
    Anticancer Res. 2023;43:3571-3577.
    PubMed         Abstract available

    BMC Cancer

  16. MITCHELL H, Mclean J, Gavin AT, Visser O, et al
    Impact of COVID-19 control on lung, breast, and colorectal pathological cancer diagnoses. A comparison between the Netherlands, Aotearoa New Zealand, and Northern Ireland.
    BMC Cancer. 2023;23:700.
    PubMed         Abstract available

  17. JIANG Y, Zhang J, Zhong J, Liao H, et al
    Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients.
    BMC Cancer. 2023;23:702.
    PubMed         Abstract available

  18. MERTENS E, Barrenechea-Pulache A, Sagastume D, Vasquez MS, et al
    Understanding the contribution of lifestyle in breast cancer risk prediction: a systematic review of models applicable to Europe.
    BMC Cancer. 2023;23:687.
    PubMed         Abstract available

  19. CHITRANGI S, Vaity P, Jamdar A, Bhatt S, et al
    Patient-derived organoids for precision oncology: a platform to facilitate clinical decision making.
    BMC Cancer. 2023;23:689.
    PubMed         Abstract available


  20. Breast cancer mortality in 500 000 women with early invasive breast cancer in England, 1993-2015: population based observational cohort study.
    BMJ. 2023;382:p1744.

    Br J Cancer

  21. LIEFAARD MC, Moore KS, Mulder L, van den Broek D, et al
    Correction To: Tumour-educated platelets for breast cancer detection: biological and technical insights.
    Br J Cancer. 2023 Jul 24. doi: 10.1038/s41416-023-02371.

    Breast Cancer

  22. JESUS OJ, Luis CP, Matilde MF
    Effects of exercise on cancer-related cognitive impairment in breast cancer survivors: a scoping review.
    Breast Cancer. 2023 Jul 22. doi: 10.1007/s12282-023-01484.
    PubMed         Abstract available

  23. FUTAMURA M, Nakayama T, Yoshinami T, Oshiro C, et al
    Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Breast Cancer. 2023 Jul 24. doi: 10.1007/s12282-023-01485.
    PubMed         Abstract available

  24. CHEN ST, Lai HW, Chang JH, Liao CY, et al
    Diagnostic accuracy of pre-operative breast magnetic resonance imaging (MRI) in predicting axillary lymph node metastasis: variations in intrinsic subtypes, and strategy to improve negative predictive value-an analysis of 2473 invasive breast cancer p
    Breast Cancer. 2023 Jul 27. doi: 10.1007/s12282-023-01488.
    PubMed         Abstract available

  25. KAWAMURA C, Iwagami M, Sun Y, Komiyama J, et al
    Factors associated with non-participation in breast cancer screening: analysis of the 2016 and 2019 comprehensive survey of living conditions in Japan.
    Breast Cancer. 2023 Jul 25. doi: 10.1007/s12282-023-01486.
    PubMed         Abstract available

    Breast Cancer Res

  26. CHUANGCHOT N, Jamjuntra P, Yangngam S, Luangwattananun P, et al
    Enhancement of PD-L1-attenuated CAR-T cell function through breast cancer-associated fibroblasts-derived IL-6 signaling via STAT3/AKT pathways.
    Breast Cancer Res. 2023;25:86.
    PubMed         Abstract available

  27. ADAM R, Dell'Aquila K, Hodges L, Maldjian T, et al
    Deep learning applications to breast cancer detection by magnetic resonance imaging: a literature review.
    Breast Cancer Res. 2023;25:87.
    PubMed         Abstract available

  28. ZHENG C, Xu X, Wu M, Xue L, et al
    Neutrophils in triple-negative breast cancer: an underestimated player with increasingly recognized importance.
    Breast Cancer Res. 2023;25:88.
    PubMed         Abstract available

  29. MOHL A, Behrens S, Flasskamp F, Obi N, et al
    The impact of cardiovascular disease on all-cause and cancer mortality: results from a 16-year follow-up of a German breast cancer case-control study.
    Breast Cancer Res. 2023;25:89.
    PubMed         Abstract available

    Breast Cancer Res Treat

  30. MARIAPUN S, Ho WK, Eriksson M, Tai MC, et al
    Evaluation of SNPs associated with mammographic density in European women with mammographic density in Asian women from South-East Asia.
    Breast Cancer Res Treat. 2023;201:237-245.
    PubMed         Abstract available

  31. FRIEDMAN R, Spiegel DY, Kinney J, Willcox J, et al
    Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention.
    Breast Cancer Res Treat. 2023;201:299-305.
    PubMed         Abstract available

  32. SCHANDIZ H, Park D, Kaiser YL, Lyngra M, et al
    Subtypes of high-grade breast ductal carcinoma in situ (DCIS): incidence and potential clinical impact.
    Breast Cancer Res Treat. 2023;201:329-338.
    PubMed         Abstract available

  33. ADACHI Y, Asaga S, Kumamaru H, Kinugawa N, et al
    Analysis of prognosis in different subtypes of invasive lobular carcinoma using the Japanese National Cancer Database-Breast Cancer Registry.
    Breast Cancer Res Treat. 2023 Jul 21. doi: 10.1007/s10549-023-07022.
    PubMed         Abstract available

  34. LIU X, Wang M, Wang Q, Zhang H, et al
    Diagnostic value of contrast-enhanced ultrasound for sentinel lymph node metastasis in breast cancer: an updated meta-analysis.
    Breast Cancer Res Treat. 2023 Jul 27. doi: 10.1007/s10549-023-07063.
    PubMed         Abstract available

  35. CLELLAND EN, Rothschild HT, Patterson A, Molina-Vega J, et al
    Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    Breast Cancer Res Treat. 2023 Jul 27. doi: 10.1007/s10549-023-07059.
    PubMed         Abstract available

  36. VAN HAAREN ERM, Poodt IGM, Spiekerman van Weezelenburg MA, van Bastelaar J, et al
    Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide cohort of breast cancer patients.
    Breast Cancer Res Treat. 2023 Jul 27. doi: 10.1007/s10549-023-07065.
    PubMed         Abstract available

  37. FALTINOVA M, Vehmanen L, Lyytinen H, Haanpaa M, et al
    Effects of letrozole on serum estradiol and estrone in postmenopausal breast cancer patients and tolerability of treatment: a prospective trial using a highly sensitive LC-MS/MS (liquid chromatography-tandem mass spectrometry) method for estrogen meas
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07054.
    PubMed         Abstract available

  38. MUENDLEIN A, Heinzle C, Brandtner EM, Leiherer A, et al
    Plasma apolipoprotein M predicts overall survival in metastatic breast cancer patients.
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07045.
    PubMed         Abstract available

  39. DOLEGA-KOZIEROWSKI B, Kasprzak P, Lis M, Szynglarewicz B, et al
    Numerical and physical modeling of breast cancer based on image fusion and artificial intelligence.
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07056.
    PubMed         Abstract available

  40. WAAIJER MEC, Lemij AA, de Boer AZ, Bastiaannet E, et al
    The impact of geriatric characteristics and comorbidities on distant metastases and other cause mortality in older women with non-metastatic breast cancer treated with primary endocrine therapy.
    Breast Cancer Res Treat. 2023 Jul 21. doi: 10.1007/s10549-023-07029.
    PubMed         Abstract available

  41. UGURLU MU, Bugdayci O, Akmercan A, Kaya H, et al
    Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07041.
    PubMed         Abstract available

  42. SMEDSLAND SK, Vandraas KF, Falk RS, Horn J, et al
    Sexual health in long-term breast cancer survivors: a comparison with female population controls from the HUNT study.
    Breast Cancer Res Treat. 2023 Jul 25. doi: 10.1007/s10549-023-07021.
    PubMed         Abstract available

  43. KOBAYASHI K, Masuda N, Mizuno T, Miura K, et al
    Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03).
    Breast Cancer Res Treat. 2023 Jul 22. doi: 10.1007/s10549-023-07030.
    PubMed         Abstract available

  44. STAFFORD L, Sinclair M, Butow P, Hughes J, et al
    Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study.
    Breast Cancer Res Treat. 2023 Jul 22. doi: 10.1007/s10549-023-07039.
    PubMed         Abstract available

    Breast J

  45. EL-HELOU E, Eddy C, Picchia S, Van de Merckt C, et al
    Effectiveness of Carbon Localization for Invasive Breast Cancer: An Institutional Experience.
    Breast J. 2023;2023:4082501.
    PubMed         Abstract available


  46. GEFFEN SR, Poteat T, Dean LT, Malone J, et al
    Engaging black sexual minority women in breast cancer research: Lessons in community partnerships.
    Cancer. 2023 Jul 25. doi: 10.1002/cncr.34960.
    PubMed         Abstract available

    Clin Breast Cancer

  47. CONROY M, Kamaraju S, Powell M, Harris A, et al
    Racial and Ethnic Differences in the Use of Electronic Medical Record Messaging Among Patients With Breast Cancer: A Quality Improvement Study.
    Clin Breast Cancer. 2023 Jul 4:S1526-8209(23)00172.
    PubMed         Abstract available

  48. DING W, Ye D, Zhu H, Lin Y, et al
    Survival Benefit of Adjuvant Chemotherapy in Node-Positive Breast Cancer With a 21-Gene Recurrence Score of 14 to 25: A Real-World Study Based on the Inverse Probability of Treatment Weighting Method.
    Clin Breast Cancer. 2023 Jul 15:S1526-8209(23)00190.
    PubMed         Abstract available

    Clin Cancer Res

  49. MEDFORD AJ, Moy B, Spring LM, Hurvitz SA, et al
    Molecular Residual Disease in Breast Cancer: Detection and Therapeutic Interception.
    Clin Cancer Res. 2023 Jul 21:CCR-23-0757. doi: 10.1158/1078-0432.CCR-23-0757.
    PubMed         Abstract available

  50. PASCUAL J, Gil-Gil M, Proszek P, Zielinski C, et al
    Baseline mutations and ctDNA dynamics as prognostic and predictive factors in ER-positive/HER2-negative metastatic breast cancer patients.
    Clin Cancer Res. 2023 Jul 25:CCR-23-0956. doi: 10.1158/1078-0432.CCR-23-0956.
    PubMed         Abstract available

    Discov Oncol

  51. LI X, Chen Y, Wang T, Liu Z, et al
    GPR81-mediated reprogramming of glucose metabolism contributes to the immune landscape in breast cancer.
    Discov Oncol. 2023;14:140.
    PubMed         Abstract available

    Int J Cancer

  52. ROCHE ME, Ko YH, Domingo-Vidal M, Lin Z, et al
    TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer.
    Int J Cancer. 2023 Jul 27. doi: 10.1002/ijc.34660.
    PubMed         Abstract available

    J Clin Invest

  53. DEVARAJAN R, Izzi V, Peltoketo H, Rask G, et al
    Targeting collagen XVIII improves the efficiency of ErbB inhibitors in breast cancer models.
    J Clin Invest. 2023 Jul 27:e159181. doi: 10.1172/JCI159181.
    PubMed         Abstract available

    J Natl Cancer Inst

  54. SYMONDS LK, Davidson NE
    Are we there yet? Optimal duration of endocrine therapy in women with postmenopausal early-stage hormone receptor-positive breast cancer.
    J Natl Cancer Inst. 2023 Jun 30:djad111. doi: 10.1093.

    Nat Rev Cancer

  55. WILL M, Liang J, Metcalfe C, Chandarlapaty S, et al
    Therapeutic resistance to anti-oestrogen therapy in breast cancer.
    Nat Rev Cancer. 2023 Jul 27. doi: 10.1038/s41568-023-00604.
    PubMed         Abstract available


  56. NISHIMURA T, Kakiuchi N, Yoshida K, Sakurai T, et al
    Evolutionary histories of breast cancer and related clones.
    Nature. 2023 Jul 26. doi: 10.1038/s41586-023-06333.
    PubMed         Abstract available

    NPJ Breast Cancer

  57. YANG Y, He Y, Fan Z, Chen X, et al
    Author Correction: Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trial.
    NPJ Breast Cancer. 2023;9:62.


  58. GUO L, Zhang W, Zhang X, Wang J, et al
    A novel transcription factor SIPA1: identification and verification in triple-negative breast cancer.
    Oncogene. 2023 Jul 27. doi: 10.1038/s41388-023-02787.
    PubMed         Abstract available

    PLoS One

  59. LEE YJ, Yoo TK, Kim J, Chung IY, et al
    Survival outcomes of breast cancer patients with recurrence after surgery according to period and subtype.
    PLoS One. 2023;18:e0284460.
    PubMed         Abstract available

  60. FISCON G, Funari A, Paci P
    Circular RNA mediated gene regulation in human breast cancer: A bioinformatics analysis.
    PLoS One. 2023;18:e0289051.
    PubMed         Abstract available

  61. JAVAN BIPARVA A, Raoofi S, Rafiei S, Masoumi M, et al
    Global depression in breast cancer patients: Systematic review and meta-analysis.
    PLoS One. 2023;18:e0287372.
    PubMed         Abstract available

  62. FANG Q, Xin W, Chen L, Fu Y, et al
    Caffeic acid phenethyl ester suppresses metastasis of breast cancer cells by inactivating FGFR1 via MD2.
    PLoS One. 2023;18:e0289031.
    PubMed         Abstract available

  63. OZ M, King JR, Yang KS, Khushaish S, et al
    alpha7 nicotinic acetylcholine receptor interaction with G proteins in breast cancer cell proliferation, motility, and calcium signaling.
    PLoS One. 2023;18:e0289098.
    PubMed         Abstract available

  64. NICKEL B, McCaffery K, Jansen J, Barratt A, et al
    Women's views about current and future management of Ductal Carcinoma in Situ (DCIS): A mixed-methods study.
    PLoS One. 2023;18:e0288972.
    PubMed         Abstract available

    Radiol Imaging Cancer

  65. RAM S
    One Size Fits All?-Not Anymore: Personalizing Breast Cancer Treatment with Use of a Semiautomated Functional Tumor Volume-based Predictive Model in the Assessment of Neoadjuvant Therapy Response.
    Radiol Imaging Cancer. 2023;5:e230089.

  66. TON L, Chung M
    Updated Recommendations by the American College of Radiology for Breast Cancer Screening in Individuals at Higher-Than-Average Risk.
    Radiol Imaging Cancer. 2023;5:e239015.

  67. HOUSER M, Rapelyea JA
    Using Synthetic MRI and Radiomics to Predict Treatment Response in Triple-Negative Breast Cancer.
    Radiol Imaging Cancer. 2023;5:e230095.

  68. HWANG KP, Elshafeey NA, Kotrotsou A, Chen H, et al
    A Radiomics Model Based on Synthetic MRI Acquisition for Predicting Neoadjuvant Systemic Treatment Response in Triple-Negative Breast Cancer.
    Radiol Imaging Cancer. 2023;5:e230009.
    PubMed         Abstract available

  69. ONISHI N, Bareng TJ, Gibbs J, Li W, et al
    Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment.
    Radiol Imaging Cancer. 2023;5:e220126.
    PubMed         Abstract available


  70. SHI Z, Huang X, Cheng Z, Xu Z, et al
    Erratum for: MRI-based Quantification of Intratumoral Heterogeneity for Predicting Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer.
    Radiology. 2023;308:e239021.

    Radiother Oncol

  71. LE BRAS A, Belkacemi Y, Bourgier C, Gabelle-Flandin I, et al
    Economic evaluation and budget-impact of accelerated partial breast irradiation (APBI) versus standard or hypofractionated whole breast irradiation (WBI) in postmenopausal women with early-stage breast cancer. Results from the French SHARE randomized
    Radiother Oncol. 2023 Jul 20:109818. doi: 10.1016/j.radonc.2023.109818.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.